We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Scancell Holdings Plc | LSE:SCLP | London | Ordinary Share | GB00B63D3314 | ORD 0.1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 11.50 | 11.00 | 12.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -5.86M | -0.0063 | -18.25 | 106.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
10/12/2024 17:01 | My posts are purely educational Sci102. I've all the crypto I need....fortunately ! Did I mention that Bitcoin is the MOST lucrative asset humans beings have EVER known ? | 2tyke | |
10/12/2024 15:34 | Finally, I found a " link" between OXB and SCLP.For the few of us that have both.Not sure what Alexander likes, but... HTTps://www.linkedin | pharmaboy3 | |
10/12/2024 15:30 | Took your time Roger!!! He clearly parted company with his trolley a long time ago. | chilltime | |
10/12/2024 15:06 | Hey tyke. Since you like crypto so much, perhaps you should try getting more "coins" from your posts. The advfn coins are actually a cryptocurrency promoting mechanism that gives you free crypto coins. So how about you focused on that :) | sci102 | |
10/12/2024 13:08 | Lol.... The only laugh inane will get is peeps laughing AT him....as usual. Dom......bankers don't end up rich and powerful...they are usually idiots. They end up getting 'bailed out' by tax payers unfortunately ! The market is a place of irony....and complete contradiction. | 2tyke | |
10/12/2024 12:25 | Of course you don't know what it means, because you are a complete fool.......But you still try to tell the guy how to do his job?? Moron! | markingtime | |
10/12/2024 12:20 | Roger you talk as if I care🤣㊃ | sci102 | |
10/12/2024 12:18 | Sc102 You seem to be very bitter, Filtered. | rogerbridge | |
10/12/2024 12:15 | What I am saying is that this raise is not removing the uncertainty of how the phase2/3 will be funded. And that only very recently the company said they would not need any more funds to get to that point. However, the latter is the minor of the two as everyone knows by now that the company's word means nothing :) I guess I've never been an "FD" since I don't even know what that means :) | sci102 | |
10/12/2024 12:09 | #15257 Sci102 Clearly you have not twigged that every 'development' company raises money any time that it can. The progress RNS should have enabled a better price for the placing but it looks like it was not best managed. | dominiccummings | |
10/12/2024 12:00 | The share price is down to a year or two of market abandonment. City vultures have picked off what they can through 90% discounts in many cases. Some companies have left the AIM as they couldn’t raise funds. Others diluted into oblivion, good business cases or not. Scancell was diluted heavily when Redmile and Vulpes appeared, but without those funds recognising the relatively unique science (cancer targets) that the industry had missed. Without that backing Scancell would sadly be in a far more precarious situation. It has provided the lifeline to show what Vulpes and Redmile could see, that it works and has massive potential. How many shares are in issue is a stupid point. It’s end game, earnings, buy out price etc that counts. Meanwhile the retail masses appear to be still chasing some heavily over-priced junk looking companies that will cost them dearly, hooked on hype, ignoring common sense. | chilltime | |
10/12/2024 11:56 | I can see you've never been an FD. | markingtime | |
10/12/2024 11:37 | Dom and MT, Less than 2 months ago the company said they had enough cash to get to the readouts they need to negotiate a deal that would move immunobody to later stage trials. Yet recently they raised more cash to fund the extended timelines, so the uncertainty around funding of the phase2/3 has been extended to Q4 2025 imo, except with 72% ORR so far instead of 85%. On the other hand, they have a second deal from the glymab platform which is great. In addition, I think it is reasonable to hope that good news from modi-1 in 2025 and hopefully a milestone payment from the first glymab deal, also in 2025, could bring the company in a much better position. None of these things happened yet and there is still a lot of "hope" involved so I wouldn't rush to commend the all in strategy just yet. | sci102 | |
10/12/2024 08:58 | 15p is indeed a shocking performance over the last few years. But ultimately, when the scramble comes, it'll be the likes of Inanaco who get the last laugh.....just as it has been for shareholders of many other disruptive novel technologies over the last few decades. | markingtime | |
10/12/2024 08:05 | Another snippet from Macmillan chat. No direct mention about Scancell on this one but there is optimism in the vaccine field now; "Her oncologist is very optimistic that new cancer vaccines will be coming soon, and could be a gamechanger." | marcusl2 | |
09/12/2024 23:01 | If you want big solid funds backing you then retail have to be at the back of the queue. The AIM companies that serve retail typically serve up endless too good to be true bullsh”t and leave them destroyed. Some AIM shares are still punching way above their weight in value terms. Held there by retail masses chasing a hopeless cause, in the end they will collapse. Scancell has the science to changes lives and has the backers to get there. The Tigit mab chasing lot, just a few years ago were paying $200m up front for pre clinical candidates. DNA vaccines, and Glymabs are part of the upcoming new way that will excite the industry. | chilltime | |
09/12/2024 21:09 | No way logman. The good news will take a little time to sink in bt it'll make 15p in less than a month. I feel we all underestimate the one-sided nature of the fund raise. We do it a handful of times but lined up against us, all lovely people with all the chat, are folks doing it every week, with their own selfish interests. (That's why bankers end up rich and powerful!). | dominiccummings | |
09/12/2024 20:55 | You may be correct fragma. But 15p is a shocking performance with the amount of shares in issue now. | thelogman | |
09/12/2024 20:50 | 15p plus coming | fragma | |
09/12/2024 20:33 | Sub 10 p coming. | thelogman | |
09/12/2024 20:30 | And before anyone says scancell are doing their utmost to find treatments , I totally agree.But like just about every aim share they do not give a tuck for private investors absolute shambles . Tuck should be swear words but would not let me. | thelogman | |
09/12/2024 18:44 | Serratia, after all these years, someone got the reference! | fragma | |
09/12/2024 18:35 | Toca's miracle. | serratia |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions